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1682-606X/Copyright ª 2015, TaiwanAbstract Glioblastoma multiforme is the most common and aggressive primary malignant
brain tumor and usually invades the intracranial space. Extracranial invasion is uncommon,
and skin invasions are even less common. Here, we present an extremely rare case of aggres-
sive skin invasion by glioblastoma multiforme. Once skin invasion occurs, its spread is too rapid
to be resectable in only a few weeks and is often accompanied by deterioration of the primary
lesion and short-term survival. Recognizing small cutaneous tumors adjacent to a previous sur-
gical site is vital at the initial stage of skin invasion. Early recognition of cutaneous lesions,
resection, and pathological confirmation, followed by chemotherapy and radiotherapy, may
be beneficial for these patients.
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Glioblastoma multiforme (GBM) is the most common pri-
mary brain tumor and the most malignant of the astrocy-
tomas, representing w12e15% of all intracranial tumors
and 50e75% of astrocytomas. GBM is an aggressive malig-
nant astrocytoma classified as a World Health Organization
Grade IV astrocytoma and has poor differentiation. The
mean survival time of affected patients is usually < 2
years.1 GBMs have various spread patterns, including white-
matter metastases, which is the most common route,Elsevier Taiwan LLC. All rights reserved.
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subependymal spread, skulledura invasion, and extra-
central nervous system (CNS) metastases.2 Cases of extra-
cranial lesions are < 2%, with the lung and pleura, regional
lymph nodes, spine, bone marrow, and liver being common
sites.3 In this study, in addition to reviewing relevant
literature, we present an extremely rare and devastating
case of regional skin invasion by GBM.Figure 2 MRI (T2 þ contrast) findings in a 50-year-old woman
with glioblastoma multiforme. An intracranial tumor is present
on the left frontaleparietal area and a large mass with sub-
dural and scalp invasion along the previous surgical site is
observed. MRI Z magnetic resonance imaging.2. Case Report
In December 2012, a 50-year-old woman presented with
right hemiparesis with a muscle power of 3e4 and Broca’s
aphasia. Imaging studies revealed the presence of a brain
tumor on the left frontaleparietal area with peritumoral
edema, for which she underwent immediate surgery. The
tumor was pathologically confirmed to be GBM and after
surgery, her clinical symptoms improved. Two weeks after
the operation, she was administered concurrent radio-
therapy with 6000 cGy for 30 courses and chemotherapy
with temozolomide at 75 mg/m2/d for 42 days. Addition-
ally, she received a 5-day course of adjuvant chemotherapy
with temozolomide at 200 mg/m2/d every 28 days.
In May 2013, a small, firm, round, and immobile scalp
tumor measuring 1 cm  2 cm, with no inflammatory
change or active bleeding, was noted adjacent to the pre-
vious craniotomy site. The tumor showed rapid progression
in 1.5 months, with contiguous spread to the scalp, left
preauricular area, and left neck (Figure 1). The lesions
were characterized by firm, solid, multiple, and immobile
nodules with no pus discharge, but easy bleeding. The pa-
tient also presented with worsening right hemiparesis and
dysarthria. Magnetic resonance imaging (MRI) revealed
cutaneous tumors in the subgaleal space, subcutaneous
layer of the preauricular space, and left neck and recur-
rence of intracranial GBM with peritumoral edema
(Figure 2). Resection of the tumor, including cutaneous and
intracranial lesions, was planned. During surgery, no gross
invasion of the dura matter and the bone flap by the tumors
was observed (Figure 3). However, the patient died becauseFigure 1 Glioblastoma multiforme with extracranial metas-
tasis in a 50-year-old woman. Skin invasion progressed rapidly
from a small scalp nodule to fulminant multiple lesions.of rapid neurological deterioration and respiratory failure 3
months after the scalp tumor was first recognized.
Specimens from the subgaleal and subcutaneous lesions
showed necrosis with dermal and subdermal infiltration
(Figure 4). The tumors contained spindle-shaped, highly
pleomorphic cells with abundant mitoses, necrosis, and
microvascular proliferation and marked nuclear atypia.
Immunostaining was positive for glial fibrillary acidic pro-
tein (GFAP). Immunohistochemistry of both primary
parenchymal and cutaneous tumors showed similar features
of focal GFAP positivity. These histological features
confirmed skin invasion by GBM.3. Discussion
GBM is the most common and aggressive primary brain
tumor in adults and is characterized by a high local recur-
rence rate. It is the most common primary CNS tumor that
causes “brain to brain” invasion. Dissemination to the pons,
cerebellum, medulla, and spinal cord can also occur along
the compact white tracts, including the corpus callosum,
anterior commissure, fornices, and corticospinal tract.
Other routes of intracranial spread include CSF dissemina-
tion, ependymal and subependymal spread, and skulledura
invasion. However, extracranial spread is rare, with an
incidence rate of < 0.4e2%.4 The first case of lung metas-
tasis was reported in 1928 by Davis,5 and to date, only
200e300 cases have been reported in the literature.3,6,7
Although the mechanisms underlying extracranial spread
remain unknown, some hypotheses have been proposed8 to
explain such low metastatic rates. First, patients do not
survive long enough to have detectable extracranial inva-
sion because they often have rapid enlargement of the
brain tumor, which causes brain herniation and death.
Second, the brain is physically protected by the thick
basement membrane of the bloodebrain barrier. Third, the
absence of a lymphatic system in the brain appears to
prevent distant spread.
Figure 3 Gross intraoperative findings in a 50-year-old woman with recurrent and extracranial glioblastoma multiforme. The
dura (A) and bone flap (B, C) are shown.
Figure 4 Pathologic and immunohistochemical examination of a glioblastoma multiforme scalp lesion. H&E staining at (A) 40
and (B) 10 magnifications: the tumor shows necrosis and dermal and subdermal infiltration. H&E staining at (C) 400 magnifi-
cation: the tumor contains highly pleomorphic cells with abundant mitoses, necrosis, and microvascular proliferation and marked
nuclear atypia. Immunohistochemical staining for GFAP at (D) 200 magnification: tumor cells are strongly positive for GFAP.
GFAP Z glial fibrillary acidic protein; H&E Z hematoxylin and eosin.
174 T.-L. Wang et al.Up to 80% of extracranial cases have undergone surgical
procedures, such as craniotomy and ventriculoperitoneal
shunt.2,7 However, because extracranial spread occurs
after surgery in a high proportion of these cases, some
casual relationship may exist that accounts for changes in
the brain microenvironment. The lymphatic system, blood
vessels, and artificial shunts have been proposed as routes
of extracranial spread. However, access to extracranial
sites alone is insufficient for extracranial spread, as local
factors in the host organ also play crucial roles. Sub-
ramanian et al2 summarized several factors contributing to
metastases, including genetic composition, extracellular
matrix components, adhesion molecules, cell motility and
cytoskeleton, enzyme action, and growth factors and cy-
tokines. The cell types of GBM are considerably unique,with most of these cells unable to survive outside of brain
tissues.
Only 11 cases of regional skin invasion have been re-
ported in the literature (Table 1). The first case of cuta-
neous metastasis was documented in 2002.9 As mentioned
earlier, cutaneous metastases can occur through the
lymphatic system and blood vessels. However, unlike other
common sites of extracranial lesions, such as the lung,
pleura, and bone, the skin at the surgical site has more
likelihood of direct contact with and grafting of cells of
GBMs during surgical procedures. Implantation of tumor
cells at the time of surgery has also been reported in some
cases.9 Direct contact with and grafting of tumor cells on
adjacent skin are possible, therefore, theoretically, skin
invasion by GBMs should occur at a higher frequency as
Table 1 Summary of literature on skin invasion by GBMs.
Study Sex Age
(y)
Time interval from
surgery to skin
invasion (mo)
Time interval from
skin invasion to
death (mo)
Postoperative treatment Surgical procedures for
skin invasion
Intracranial recurrence
at the time of
skin invasion
Figueroa
et al9 (2002)
M 34 8 3 Radiotherapy (6480 cGy) Total resection þ
Allan
et al10 (2004)
M 60 12 2 Radiotherapy e þ
Bouillot-Eimer
et al11 (2005)
F 60 8 4 Radiotherapy (6000 cGy)
and chemotherapy
(Carmustine)
Partial resection þ
Jain et al12 (2005) M 49 10 2 Radiotherapy Total resection þ
Saad et al13 (2007) M 13 9 1 Radiotherapy (5940 cGy)
and chemotherapy (TMZ)
e þ
Mentrikoski
et al14 (2008)
F 58 16 Not reported Radiotherapy and
chemotherapy (TMZ,
bevacizumab)
Biopsy þ
Miliaras
et al15 (2009)
M 63 7 3 Not reported Biopsy þ
Senetta
et al16 (2009)
F 48 12 4 Radiotherapy and
chemotherapy (TMZ)
Total resection 
F 53 Not reported 6 Radiotherapy and
chemotherapy (TMZ)
Biopsy 
Guo et al17 (2012) F 19 8 Not reported Radiotherapy (6000 cGy)
and chemotherapy
Total resection þ
Ginat et al18(2013) M 62 10 14.5 Radiotherapy (6000 cGy)
and chemotherapy
Total resection þ
GBM Z glioblastoma multiforme; TMZ Z temozolomide.
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176 T.-L. Wang et al.compared to distant spread to other locations. We propose
two hypotheses to explain the low metastatic rate. First,
whole-brain radiotherapy for GBM patients after surgery
may decrease skin invasion.19 Second, the microenviron-
ment of the skin is extremely crucial for GBM harvesting,
since glial cells are unique and require an intracranial
environment to survive.
Early recognition of cutaneous tumors in GBM patients is
vital. Because the growth of such tumors is rapid, they can
become unresectable in only a few weeks. Some patients
can only undergo partial resection or biopsy due to delayed
recognition and resection, as in our case. To date, the
cutaneous lesions of only five patients have been
completely ablated, and other patients only underwent
biopsy or partial excision. These unresectable scalp lesions
often increase patient suffering because of its negative
impact on the patient appearance and quality of life. The
incidence of these metastases can be reduced by surgical
techniques, including watertight approximation of the
dura, replacement of the bone flap, and alteration of sur-
gical instruments once the intradural component of the
surgery is completed.
The literature review revealed that most patients with
skin invasion often have worsening intracranial GBM. In our
review, the mean survival time was 4.4 months in nine of
the 11 patients following initial recognition of skin invasion.
Compared with other metastatic cases, the median survival
time from the detection of metastases to death was 1.5
months,6 with patients usually dying due to rapid progres-
sion of intracranial lesions. Early recognition of cutaneous
lesions, resection, and pathologic confirmation, followed
by radiotherapy and chemotherapy with temozolomide, are
recommended and may be beneficial.17
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